Literature DB >> 33028619

Inflammation Unrestrained by SIRPα Induces Secondary Hemophagocytic Lymphohistiocytosis Independent of IFN-γ.

Koby Kidder1, Zhen Bian1,2, Lei Shi1,2, Yuan Liu3,2.   

Abstract

A hallmark of secondary hemophagocytic lymphohistiocytosis (sHLH), a severe form of cytokine storm syndrome, is the emergence of overactivated macrophages that engulf healthy host blood cells (i.e., hemophagocytosis) and contribute to the dysregulated inflammation-driven pathology. In this study, we show that depleting SIRPα (SIRPα-/-) in mice during TLR9-driven inflammation exacerbates and accelerates the onset of fulminant sHLH, in which systemic hemophagocytosis, hypercytokinemia, consumptive cytopenias, hyperferritinemia, and other hemophagocytic lymphohistiocytosis hallmarks were apparent. In contrast, mice expressing SIRPα, including those deficient of the SIRPα ligand CD47 (CD47-/-), do not phenocopy SIRPα deficiency and fail to fully develop sHLH, albeit TLR9-inflamed wild-type and CD47-/- mice exhibited hemophagocytosis, anemia, and splenomegaly. Although IFN-γ is largely considered a driver of hemophagocytic lymphohistiocytosis pathology, IFN-γ neutralization did not preclude the precipitation of sHLH in TLR9-inflamed SIRPα-/- mice, whereas macrophage depletion attenuated sHLH in SIRPα-/- mice. Mechanistic studies confirmed that SIRPα not only restrains macrophages from acquiring a hemophagocytic phenotype but also tempers their proinflammatory cytokine and ferritin secretion by negatively regulating Erk1/2 and p38 activation downstream of TLR9 signaling. In addition to TLR9 agonists, TLR2, TLR3, or TLR4 agonists, as well as TNF-α, IL-6, or IL-17A, but not IFN-γ, similarly induced sHLH in SIRPα-/- mice but not SIRPα+ mice. Collectively, our study suggests that SIRPα plays a previously unappreciated role in sHLH/cytokine storm syndrome pathogenesis by preventing macrophages from becoming both hemophagocytic and hyperactivated under proinflammation.
Copyright © 2020 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33028619      PMCID: PMC7658050          DOI: 10.4049/jimmunol.2000652

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  78 in total

1.  Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice.

Authors:  Edward M Behrens; Scott W Canna; Katharine Slade; Sheila Rao; Portia A Kreiger; Michele Paessler; Taku Kambayashi; Gary A Koretzky
Journal:  J Clin Invest       Date:  2011-05-16       Impact factor: 14.808

2.  Role of CD47 as a marker of self on red blood cells.

Authors:  P A Oldenborg; A Zheleznyak; Y F Fang; C F Lagenaur; H D Gresham; F P Lindberg
Journal:  Science       Date:  2000-06-16       Impact factor: 47.728

Review 3.  Phagocytosis: An Immunobiologic Process.

Authors:  Siamon Gordon
Journal:  Immunity       Date:  2016-03-15       Impact factor: 31.745

Review 4.  Hemophagocytic Lymphohistiocytosis.

Authors:  Hanny Al-Samkari; Nancy Berliner
Journal:  Annu Rev Pathol       Date:  2017-09-13       Impact factor: 23.472

5.  Functional elements on SIRPalpha IgV domain mediate cell surface binding to CD47.

Authors:  Yuan Liu; Qiao Tong; Yubin Zhou; Hsiau-Wei Lee; Jenny J Yang; Hans-Jörg Bühring; Yi-Tien Chen; Binh Ha; Celia X-J Chen; Yang Yang; Ke Zen
Journal:  J Mol Biol       Date:  2006-10-03       Impact factor: 5.469

6.  Macrophage depletion in the rat after intraperitoneal administration of liposome-encapsulated clodronate: depletion kinetics and accelerated repopulation of peritoneal and omental macrophages by administration of Freund's adjuvant.

Authors:  J Biewenga; M B van der Ende; L F Krist; A Borst; M Ghufron; N van Rooijen
Journal:  Cell Tissue Res       Date:  1995-04       Impact factor: 5.249

Review 7.  Making sense of the cytokine storm: a conceptual framework for understanding, diagnosing, and treating hemophagocytic syndromes.

Authors:  Scott W Canna; Edward M Behrens
Journal:  Pediatr Clin North Am       Date:  2012-04       Impact factor: 3.278

8.  Effective treatment of severe COVID-19 patients with tocilizumab.

Authors:  Xiaoling Xu; Mingfeng Han; Tiantian Li; Wei Sun; Dongsheng Wang; Binqing Fu; Yonggang Zhou; Xiaohu Zheng; Yun Yang; Xiuyong Li; Xiaohua Zhang; Aijun Pan; Haiming Wei
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-29       Impact factor: 11.205

9.  COVID-19: consider cytokine storm syndromes and immunosuppression.

Authors:  Puja Mehta; Daniel F McAuley; Michael Brown; Emilie Sanchez; Rachel S Tattersall; Jessica J Manson
Journal:  Lancet       Date:  2020-03-16       Impact factor: 79.321

10.  SIGNR1-negative red pulp macrophages protect against acute streptococcal sepsis after Leishmania donovani-induced loss of marginal zone macrophages.

Authors:  Alun C Kirby; Lynette Beattie; Asher Maroof; Nico van Rooijen; Paul M Kaye
Journal:  Am J Pathol       Date:  2009-07-30       Impact factor: 4.307

View more
  4 in total

Review 1.  Myelodysplastic syndrome and immunotherapy novel to next in-line treatments.

Authors:  Katherine Linder; Premal Lulla
Journal:  Hum Vaccin Immunother       Date:  2021-05-03       Impact factor: 3.452

2.  SARS-CoV-2-induced Overexpression of miR-4485 Suppresses Osteogenic Differentiation and Impairs Fracture Healing.

Authors:  Bobin Mi; Yuan Xiong; Chenming Zhang; Wu Zhou; Lang Chen; Faqi Cao; Fenghua Chen; Zhi Geng; Adriana C Panayi; Yun Sun; Lin Wang; Guohui Liu
Journal:  Int J Biol Sci       Date:  2021-03-25       Impact factor: 6.580

3.  Non-Lyn Src Family Kinases Activate SIRPα-SHP-1 to Inhibit PI3K-Akt2 and Dampen Proinflammatory Macrophage Polarization.

Authors:  Lei Shi; Zhen Bian; Koby Kidder; Hongwei Liang; Yuan Liu
Journal:  J Immunol       Date:  2021-08-04       Impact factor: 5.426

Review 4.  The Multiple Facets of Iron Recycling.

Authors:  Patryk Slusarczyk; Katarzyna Mleczko-Sanecka
Journal:  Genes (Basel)       Date:  2021-08-30       Impact factor: 4.096

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.